Ten years of progress in radiation oncology

Over the last decade, BMC Cancer has continuously published important research from the field of radiation oncology. Major developments in this field include the introduction of new imaging modalities into radiotherapy planning, the availability of hardware and software for more precise delivery of radiation dose, the individualization of radiotherapy concepts, for example, based on microarray data, and the combination of radiotherapy with molecular targeting approaches to overcome the radioresistance of tumor cells.

[1]  J. Debus,et al.  Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study , 2010, BMC Cancer.

[2]  W. Behnisch,et al.  Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma , 2007, BMC Cancer.

[3]  Daniela Thorwarth,et al.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.

[4]  M. Ychou,et al.  Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer , 2005, BMC Cancer.

[5]  Y. Kuo,et al.  Image-guided intensity modulated radiotherapy with helical tomotherapy for postoperative treatment of high-risk oral cavity cancer , 2011, BMC Cancer.

[6]  Claus Belka,et al.  Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition , 2005, BMC Cancer.

[7]  G. Sasso,et al.  MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer , 2010, BMC Cancer.

[8]  T. Rajkumar,et al.  A 7 gene expression score predicts for radiation response in cancer cervix , 2009, BMC Cancer.

[9]  J. Verdebout,et al.  Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis , 2001, BMC Cancer.

[10]  K. Bratengeier,et al.  Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma , 2005, BMC Cancer.

[11]  Ian F Tannock,et al.  The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors , 2010, BMC Cancer.

[12]  M. Bache,et al.  HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression , 2010, BMC Cancer.